INS and Hypoglycemia: Using data from Table 3, the U.S. annual cost of insulin- and sulfonylurea-induced hypoglycemia in older type 2 diabetic adults attaining very tight glycemic control was estimated to be U.S.$232,571,387 and U.S.$276,643,356, respectively, for a combined cost of U.S.$509,214,473.